公开(公告)号：US20200155676A1

公开(公告)日：2020-05-21

申请号：US16453650

申请日：2019-06-26

Applicant: Genentech, Inc.

Inventor： Jane GROGAN ,  Yuanyuan XIAO ,  Patrick CAPLAZI ,  Steve LIANOGLOU ,  Jason HACKNEY ,  Eugene Yu-Chuan CHIANG

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/24 ,  A61K47/62 ,  C07K16/30

Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.

公开(公告)号：US20200172620A1

公开(公告)日：2020-06-04

申请号：US16788003

申请日：2020-02-11

Applicant: Genentech, Inc.

Inventor： Yvonne M. CHEN ,  Eugene Yu-Chuan CHIANG ,  Jane Louise GROGAN ,  Simon-Peter WILLIAMS ,  Matthew Lawrence ALBERT

IPC: C07K16/28 ,  A61K35/17 ,  A61K47/65 ,  G01N33/58 ,  A61K39/00

Abstract: Provided are anti-CD8 antibodies that bind human CD8 and do not stimulate or inhibit the activation of CD8+ T cells. Also provided are nucleic acids encoding such anti-CD8 antibodies, vectors comprising such nucleic acids, host cells comprising same, and methods of making such anti-CD8 antibodies. Also provided are anti-CD8 antibodies conjugated to a detectable label. Provided are methods of using such anti-CD8 antibodies to detect CD8+ T cells in a subject, monitor disease progress in a subject having cancer, and monitor treatment progress in a subject having cancer.

公开(公告)号：US20170274073A1

公开(公告)日：2017-09-28

申请号：US15448437

申请日：2017-03-02

Applicant: Genentech, Inc.

Inventor： Jane GROGAN ,  Yuanyuan XIAO ,  Patrick CAPLAZI ,  Steve LIANOGLOU ,  Jason HACKNEY ,  Eugene Yu-Chuan CHIANG

IPC: A61K39/395 ,  C07K16/30 ,  C07K16/28

CPC classification number: A61K39/39558 ,  A61K47/62 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2300/00 ,  C07K16/244 ,  C07K16/2827 ,  C07K16/3053 ,  C07K2317/33

Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.

公开(公告)号：US20240018241A1

公开(公告)日：2024-01-18

申请号：US18346128

申请日：2023-06-30

Applicant: Genentech, Inc.

Inventor： Yvonne M. CHEN ,  Eugene Yu-Chuan CHIANG ,  Jane Louise GROGAN ,  Simon-Peter WILLIAMS ,  Matthew Lawrence ALBERT

IPC: C07K16/28 ,  A61K47/65 ,  A61K35/17 ,  A61K39/00

CPC classification number: C07K16/2815 ,  A61K47/65 ,  A61K35/17 ,  A61K39/0011 ,  A61K38/00

Abstract: Provided are anti-CD8 antibodies that bind human CD8 and do not stimulate or inhibit the activation of CD8+ T cells. Also provided are nucleic acids encoding such anti-CD8 antibodies, vectors comprising such nucleic acids, host cells comprising same, and methods of making such anti-CD8 antibodies. Also provided are anti-CD8 antibodies conjugated to a detectable label. Provided are methods of using such anti-CD8 antibodies to detect CD8+ T cells in a subject, monitor disease progress in a subject having cancer, and monitor treatment progress in a subject having cancer.